Juvenile idiopathic arthritis: current and future treatment options (Q36407354)

14 August 2017

1 reference

title

Juvenile idiopathic arthritis: current and future treatment options (English)

1 reference

juvenile rheumatoid arthritis

14 August 2017

main subject

1 reference

Giorgia Martini

1

1 reference

14 August 2017

Francesco Zulian

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

387-399

1 reference

The use of non-steroidal anti-inflammatory drugs in paediatric rheumatic diseases

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Naproxen-induced pseudoporphyria: a distinctive photodermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Utility of corticosteroid injection for temporomandibular arthritis in children with juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Intraarticular corticosteroid injection in the management of children with chronic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Intra-articular steroids in pauciarticular juvenile chronic arthritis, type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Survey of the long term incidence of osteonecrosis of the hip and adverse medical events in rheumatoid arthritis after high dose intravenous methylprednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

The mechanism of action of methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: introduction of the Dijkstra composite score

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Successfully treated sulphasalazine-induced fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia with intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Treatment of refractory juvenile idiopathic arthritis via pulse therapy using methylprednisolone and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Leflunomide or methotrexate for juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Adalimumab therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Long-term follow-up of autologous stem cell transplantation for refractory juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Calcium and vitamin D therapy in corticosteroid-induced bone loss: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Effects of intranasal salmon calcitonin in juvenile idiopathic arthritis: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.4.387

21 January 2018

Identifiers

DOI

10.1517/14656566.7.4.387

1 reference

14 August 2017

1 reference